Literature DB >> 20558012

Deriving prostate alpha-beta ratio using carefully matched groups, long follow-up and the phoenix definition of biochemical failure.

Richard Shaffer1, Tom Pickles, Richard Lee, Vitali Moiseenko.   

Abstract

PURPOSE: Prior studies have derived low values of alpha-beta ratio (a/ß) for prostate cancer of approximately 1-2 Gy. These studies used poorly matched groups, differing definitions of biochemical failure, and insufficient follow-up. METHODS AND MATERIALS: National Comprehensive Cancer Network low- or low-intermediate risk prostate cancer patients, treated with external beam radiotherapy or permanent prostate brachytherapy, were matched for prostate-specific antigen, Gleason score, T-stage, percentage of positive cores, androgen deprivation therapy, and era, yielding 118 patient pairs. The Phoenix definition of biochemical failure was used. The best-fitting value for a/ß was found for up to 90-month follow-up using maximum likelihood analysis, and the 95% confidence interval using the profile likelihood method. Linear quadratic formalism was applied with the radiobiological parameters of relative biological effectiveness = 1.0, potential doubling time = 45 days, and repair half-time = 1 hour. Bootstrap analysis was performed to estimate uncertainties in outcomes, and hence in a/ß. Sensitivity analysis was performed by varying the values of the radiobiological parameters to extreme values.
RESULTS: The value of a/ß best fitting the outcomes data was >30 Gy, with lower 95% confidence limit of 5.2 Gy. This was confirmed on bootstrap analysis. Varying parameters to extreme values still yielded best-fit a/ß of >30 Gy, although the lower 95% confidence interval limit was reduced to 0.6 Gy.
CONCLUSIONS: Using carefully matched groups, long follow-up, the Phoenix definition of biochemical failure, and well-established statistical methods, the best estimate of a/ß for low and low-tier intermediate-risk prostate cancer is likely to be higher than that of normal tissues, although a low value cannot be excluded. Crown
Copyright © 2011. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20558012     DOI: 10.1016/j.ijrobp.2009.12.058

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Letter to the Editor on: A. Siegmann et al. Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival. Results of a retrospective study. In: Strahlenther Onkol 2011;187:467-72 (No. 8) (DOI 10.1007/s00066-011-2229-3). P. Ghadjar, D. Zwahlen, D.M. Aebersold: Selection bias is not a good reason for dose intensification in patients with PSA recurrence after radical prostatectomy.

Authors:  Pirus Ghadjar
Journal:  Strahlenther Onkol       Date:  2011-11       Impact factor: 3.621

2.  Alpha/beta (α/β) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost.

Authors:  Philip S Boonstra; Jeremy M G Taylor; Beata Smolska-Ciszewska; Katarzyna Behrendt; Tomasz Dworzecki; Marzena Gawkowska-Suwinska; Brygida Bialas; Rafal Suwinski
Journal:  Br J Radiol       Date:  2016-02-23       Impact factor: 3.039

3.  Early closure of phase II prospective study on acute and late tolerance of hypofractionated radiotherapy in low-risk prostate cancer patients.

Authors:  Katarzyna Behrendt; Elżbieta Nowicka; Marzena Gawkowska-Suwińska; Grzegorz Plewicki; Beata Smolska-Ciszewska; Monika Giglok; Rafał Suwiński; Aleksander Zajusz
Journal:  Rep Pract Oncol Radiother       Date:  2014-07-15

4.  The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer.

Authors:  Beata Smolska-Ciszewska; Leszek Miszczyk; Brygida Białas; Marek Fijałkowski; Grzegorz Plewicki; Marzena Gawkowska-Suwińska; Monika Giglok; Katarzyna Behrendt; Elżbieta Nowicka; Aleksander Zajusz; Rafał Suwiński
Journal:  Radiat Oncol       Date:  2015-03-07       Impact factor: 3.481

5.  Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.

Authors:  Matthew J Boyer; Michael A Papagikos; Rex Kiteley; Zeljko Vujaskovic; Jackie Wu; W Robert Lee
Journal:  Radiat Oncol       Date:  2017-01-13       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.